🔥 Spotify Founder's Longevity Startup: Bear v Bull Case (Neko Health)
Big Picture Medicine
00:00
The Bull Case for Biomarkers
$200 is actually a low price range for all of the biomarkers that you get. If they can attract a segment of the population that won't already have been going through like annual physical exams, then that's where the winning part is. So what's the bull case here? Why is this going to be a huge thing that disrupts the market? The issue is not the tech, because we already have these tests. But the problem is how do you bring in new people? That's it.
Transcript
Play full episode
